Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.64 |
| ▸ | EBP | Q15125 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021409 | 0.93 | SIGMAR1 (0.68) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL296970 | 0.88 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL296048 | 0.88 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL296969 | 0.88 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL4024634 | 0.88 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL11412105 | 0.84 | SIGMAR1 (0.67) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL8283672 | 0.82 | SIGMAR1 (0.84) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL10138821 | 0.82 | SIGMAR1 (0.84) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL8283678 | 0.82 | SIGMAR1 (0.84) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL8283684 | 0.82 | SIGMAR1 (0.84) | SIGMAR1EBPKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | claimed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1337513-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002036570-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | SIGMAR1 837/4885EBP 3101/4885KDM4E 687/4885 |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | SIGMAR1 360/4885EBP 3668/4885KDM4E 1320/4885 |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | NQO2, TPD52L2, MLX | SIGMAR1 592/4885EBP 3612/4885KDM4E 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.